RXDX 105

Drug Profile

RXDX 105

Alternative Names: AC 013773; CEP-32496; RXDX-105

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Ignyta
  • Class Antineoplastics; Isoxazoles; Phenyl ethers; Phenylurea compounds; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 11 Sep 2017 Updated efficacy data from a phase I/Ib trial in Solid tumours presented at the 42nd European Society for Medical Oncology (ESMO-2017)
  • 11 Sep 2017 Ignyta completes enrolment in its phase I/Ib trial for Solid tumours in USA (NCT01877811)
  • 14 Aug 2017 Ignyta temporarily suspends an expanded access to RXDX 105 for Cancer in USA (NCT03052569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top